फ्लुवोक्सामिन के इंटरैक्शन

Serotonin Syndrome and Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Fluvoxamine Maleate Tablets or within 14 days of stopping treatment with Fluvoxamine Maleate Tablets is contraindicated because of an increased risk of serotonin syndrome. (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (एडोक्साबैन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (एम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Reduce the erlotinib dosage when co-administering with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor if co-administration is unavoidable [see Dosage and Administration (2.4) ]. (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Coadministration Coadministration of tizanidine, thioridazine, alosetron, or pimozide with Fluvoxamine Maleate Tablets is contraindicated [see Warnings and Precautions ( 5.4 , 5.5 , 5.6 , 5.7 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (कार्बामाज़ेपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (कोडीन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Coadministration Coadministration of tizanidine, thioridazine, alosetron, or pimozide with Fluvoxamine Maleate Tablets is contraindicated [see Warnings and Precautions ( 5.4 , 5.5 , 5.6 , 5.7 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Strong CYP1A2 inhibitors (e.g., fluvoxamine): Avoid use of HETLIOZ in combination with strong CYP1A2 inhibitors because of increased exposure ( 7.1 , 12.3 ) (टैसिमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

…(12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval >500 ms or… (ड्रोनेडेरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Coadministration Coadministration of tizanidine, thioridazine, alosetron, or pimozide with Fluvoxamine Maleate Tablets is contraindicated [see Warnings and Precautions ( 5.4 , 5.5 , 5.6 , 5.7 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Coadministration Coadministration of tizanidine, thioridazine, alosetron, or pimozide with Fluvoxamine Maleate Tablets is contraindicated [see Warnings and Precautions ( 5.4 , 5.5 , 5.6 , 5.7 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (पिरफेनिडोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पेंटाज़ोसिन और नालोक्सोन लेबल, सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पैरासिटामोल और कोडीन लेबल, सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (पोमालिडोमाइड लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

…prolong, or intensify the sedative action of other central-nervous-system depressants, such as alcohol, sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine HCl. (प्रोमेथाज़िन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (प्रोमेथाज़िन और कोडीन लेबल, दवाओं के इंटरैक्शन)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (फ्लुमाज़ेनिल लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (बेलाडोना और ओपियम लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (ब्यूटॉर्फेनॉल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Starting Fluvoxamine Maleate Tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.2 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (मेटाक्सालोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (मेथएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome and Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Fluvoxamine Maleate Tablets or within 14 days of stopping treatment with Fluvoxamine Maleate Tablets is contraindicated because of an increased risk of serotonin syndrome. (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (रेमिफेंटानिल लेबल, चेतावनियां और सावधानियां)

Ramelteon: Should not be used in combination with fluvoxamine ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Starting Fluvoxamine Maleate Tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration ( 2.5 ), Warnings and Precautions ( 5.2 )] . (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (लिसडेक्सएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (लेवॉर्फेनॉल लेबल, सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

LOREEV XR should not be used in such patients without adequate antidepressant therapy. (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

As with other psychotropic medications, patients should be advised to avoid alcohol while taking Fluvoxamine Maleate Tablets. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Anyone considering the use of Fluvoxamine Maleate Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (फ्लुवोक्सामिन लेबल, बॉक्स्ड चेतावनी)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

Serotonin Syndrome and Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Fluvoxamine Maleate Tablets or within 14 days of stopping treatment with Fluvoxamine Maleate Tablets is contraindicated because of an increased risk of serotonin syndrome. (फ्लुवोक्सामिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, सावधानियां)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Alprazolam - When fluvoxamine maleate (100 mg q.d.) and alprazolam (1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, C max , T ½ ) of alprazolam were approximately twice those observed when alprazolam was administered alone; oral clearance was reduced by about 50%. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (आइसोप्रेनालिन लेबल, दवाओं के इंटरैक्शन)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (आर्टिकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (इप्राट्रोपियम और सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )] . (उब्रोजेपेंट लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (एनाग्रेलाइड लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Strong Inhibitors of CYP2C19 : The recommended dosage is 50 mg once daily or 100 mg once daily for those patients who are not responding to 50 mg once daily. (एब्रोसिटिनिब लेबल, दवाओं के इंटरैक्शन)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Methadone: Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 Substrates APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology ( 12.3 )]. (एस्लिकार्बाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Methadone: Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…Warnings and Precautions ( 5 ) ] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

…Warnings and Precautions ( 5 ) ] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, दवाओं के इंटरैक्शन)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Since the sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive, appropriate caution should be exercised with patients who take more than one of these CNS depressants simultaneously. (कैरिसोप्रोडोल लेबल, चेतावनियां और सावधानियां)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Clozapine: Clozapine levels may be increased and produce orthostatic hypotension or seizures ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Tricyclic antidepressants Clinical Implication Concomitant use of tricyclic antidepressants with clonidine can increase blood pressure and may counteract the hypotensive effects of clonidine. (क्लोनिडिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (क्लोरोप्रोकेन लेबल, सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (ग्लाइकोपाइरोलेट लेबल, दवाओं के इंटरैक्शन)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Coadministration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (ज़ेलेप्लॉन लेबल, चेतावनियां)

Additive effects occur with concomitant use of other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol), including daytime use [see Drug Interactions (7.1) ] . (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (टरब्यूटालिन लेबल, सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Moderate CYP3A4 Inhibitors Concomitantly Used with Strong CYP2C19 Inhibitors (e.g., fluconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration… (टोफासिटिनिब लेबल, दवाओं के इंटरैक्शन)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin… (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (डैरिडोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Caution should be taken when darifenacin extended-release tablets is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants ( 7.2 ) (डैरिफेनासिन लेबल, दवाओं के इंटरैक्शन)

Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously co-administered with dofetilide as they can potentially increase dofetilide levels. (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (ड्रोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Methadone: Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (प्रिलोकेन और एड्रेनालिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Propranolol or metoprolol : Reduce dose if coadministered and titrate more cautiously ( 7.3 ). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (फाइसोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (फिनाइलएफ्रिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. (फैमोटिडीन लेबल, दवाओं के इंटरैक्शन)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (फ्लुटिकासोन और सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (बेंडामुस्टिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

…Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI) or tricyclic antidepressants may… (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Caution is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Benzodiazepines: Use with caution. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Mexiletine: Monitor serum mexiletine levels ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol or metoprolol : Reduce dose if coadministered and titrate more cautiously ( 7.3 ). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Propranolol or metoprolol : Reduce dose if coadministered and titrate more cautiously ( 7.3 ). (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Drug interactions Additive anticholinergic effects may result from concomitant use with antipsychotics, tricyclic antidepressants, and other drugs with anticholinergic effects. (मेथस्कोपोलामाइन लेबल, दवाओं के इंटरैक्शन)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (मेपिवाकेन लेबल, चेतावनियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

…5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25 mg) was… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

Strong to moderate CYP1A2 inhibitors: Co-administration may increase TIGLUTIK-associated adverse reactions ( 7.1 ) (रिलुज़ोल लेबल, दवाओं के इंटरैक्शन)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with ropinirole, adjustment of the dose of ropinirole may be required. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)

Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of NAROPIN, can interact with NAROPIN leading to increased ropivacaine plasma levels. (रोपिवाकेन लेबल, दवाओं के इंटरैक्शन)

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (रोफ्लुमिलास्ट लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (लिडोकेन लेबल, दवाओं के इंटरैक्शन)

…Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result… (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (लेवोसैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (लोमिटापाइड लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Warfarin: Plasma concentrations increased and prothrombin times prolonged; monitor prothrombin time and adjust warfarin dose accordingly ( 5.8 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (वैसोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (सिनाकैल्सेट लेबल, दवाओं के इंटरैक्शन)

…syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol. (सिलोस्टाज़ोल लेबल, दवाओं के इंटरैक्शन)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Other Drugs Affecting Hemostasis: Increased risk of bleeding with concomitant use of NSAIDs, aspirin, or other drugs affecting coagulation ( 5.8 , 5.10 ). (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (सैल्मेटेरोल लेबल, दवाओं के इंटरैक्शन)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

The concurrent use of Xyrem with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and… (सोडियम ऑक्सीबेट लेबल, चेतावनियां और सावधानियां)

Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (स्कोपोलामाइन (हायोसिन) लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Thus patients receiving oral anticoagulants and Fluvoxamine Maleate Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Discontinuation of Treatment with Fluvoxamine Maleate Tablets During marketing of Fluvoxamine Maleate Tablets and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability,… (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Effect s of HALAVEN on Other Drugs Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 enzymes or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations. (कार्बिडोपा लेबल, दवाओं के इंटरैक्शन)

(E) In vitro studies of CYP enzymes, UGTA enzymes and OATP1B1 transporter In vitro studies have shown that gemfibrozil is an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, OATP1B1, and UDP-glucuronosyltransferase (UGT) 1A1 and 1A3 (see WARNINGS ). (जेमफाइब्रोज़िल लेबल, दवाओं के इंटरैक्शन)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (टोलकैपोन लेबल, सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (डाइवैल्प्रोएक्स (वैल्प्रोएट) लेबल, दवाओं के इंटरैक्शन)

In vitro , EE is a reversible inhibitor of CYP2C19, CYP1A1 and CYP1A2 as well as a mechanism-based inhibitor of CYP3A4/5, CYP2C8, and CYP2J2. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, दवाओं के इंटरैक्शन)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants. (बेंज़ट्रोपिन लेबल, चेतावनियां)

Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Moderate inhibitors include fluconazole, fluvoxamine and clotrimazole. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

CYP1A2 Substrates Where Small Concentration Changes May Lead to Serious Adverse Reactions Clinical Impact Ritlecitinib is a CYP1A2 inhibitor. (रिटलेसिटिनिब लेबल, दवाओं के इंटरैक्शन)

In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (लोवास्टेटिन लेबल, चेतावनियां)

These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

Discontinuation of Treatment with Fluvoxamine Maleate Tablets During marketing of Fluvoxamine Maleate Tablets and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability,… (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

…quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone,… (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (एंटाकैपोन लेबल, सावधानियां)

Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

…changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (डेसलोराटाडीन लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin. (माइकाफंगिन लेबल, दवाओं के इंटरैक्शन)